Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Held by: VTI IWM IWN VXF IBB SCHA FESM VTWO IWC SCHB

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	37.23%	Shs Outstand	35.85M	Perf Week	14.47%
Market Cap	504.83M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	-0.65%	Shs Float	22.51M	Perf Month	54.05%
Enterprise Value	226.18M	PEG	-	EPS next Q	-0.77	Inst Own	35.54%	Short Float	2.48%	Perf Quarter	169.73%
Income	-75.79M	P/S	85.28	EPS this Y	65.32%	Inst Trans	2.04%	Short Ratio	1.29	Perf Half Y	222.94%
Sales	5.92M	P/B	1.82	EPS next Y	-26.44%	ROA	-23.59%	Short Interest	0.56M	Perf YTD	143.18%
Book/sh	7.74	P/C	1.77	EPS next 5Y	22.89%	ROE	-25.64%	52W High	13.68 2.92%	Perf Year	129.32%
Cash/sh	7.97	P/FCF	-	EPS past 3/5Y	-30.62% -	ROIC	-27.08%	52W Low	2.88 388.89%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.77%	Volatility	6.03% 6.63%	Perf 5Y	-
Dividend TTM	-	EV/Sales	38.21	EPS Y/Y TTM	-1.89%	Oper. Margin	-1516.29%	ATR (14)	0.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.87	Sales Y/Y TTM	-	Profit Margin	-1280.90%	RSI (14)	77.84	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	11.87	EPS Q/Q	17.81%	SMA20	20.50%	Beta	1.66	Target Price	12.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	54.19%	Rel Volume	0.45	Prev Close	13.21
Employees	64	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	151.13%	Avg Volume	432.85K	Price	14.08
IPO	Sep 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.04% 164.18%	Trades		Volume	196,868	Change	6.59%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$12
Oct-22-25	Upgrade	Citigroup	Neutral → Buy	$10
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Dec-13-25 10:35AM	2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole (Motley Fool)
Dec-04-25 09:00AM	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire) +13.88%
Nov-25-25 04:30PM	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-07-25 09:00AM	BioAge Labs to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-25 04:45PM	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Loading…
Nov-05-25 07:45AM	Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy (Motley Fool)
Oct-29-25 06:15AM	Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? (Motley Fool)
Oct-26-25 06:33PM	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Motley Fool)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +31.40%
Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
09:00AM	Loading…
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
05:45AM	Loading…
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)
Jan-01-01 12:00AM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Option Exercise	6.57	18,000	118,260	18,000	Dec 11 04:21 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0	Dec 11 04:21 PM
RUBIN PAUL D	Officer	Dec 09 '25	Proposed Sale	12.00	18,000	216,000		Dec 09 11:23 AM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Option Exercise	4.11	68,897	283,167	68,897	Dec 05 06:20 PM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Sale	10.19	68,897	701,909	0	Dec 05 06:20 PM
RUBIN PAUL D	Officer	Dec 04 '25	Proposed Sale	10.19	68,897	701,912		Dec 04 04:30 PM

Open in Screener

RAPP

Rapport Therapeutics Inc

Dec 24 • 04:00PM ET

30.93

+0.31 1.01 %

Healthcare • Biotechnology • USA • NASD

RAPP Rapport Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX BLUE REGN SAGE NBIX ACAD MRNA CRSP EDIT

| Held by: VTI IWM VXF IWN IBB XPH SCHA VTWO VHT IHE

Index	RUT	P/E	-	EPS (ttm)	-2.69	Insider Own	39.65%	Shs Outstand	47.65M	Perf Week	7.85%
Market Cap	1.47B	Forward P/E	-	EPS next Y	-3.54	Insider Trans	-0.55%	Shs Float	28.76M	Perf Month	9.22%
Enterprise Value	972.89M	PEG	-	EPS next Q	-0.66	Inst Own	68.44%	Short Float	7.76%	Perf Quarter	23.87%
Income	-97.70M	P/S	-	EPS this Y	25.15%	Inst Trans	27.19%	Short Ratio	5.02	Perf Half Y	161.90%
Sales	0.00M	P/B	2.88	EPS next Y	-25.08%	ROA	-22.55%	Short Interest	2.23M	Perf YTD	74.35%
Book/sh	10.74	P/C	2.87	EPS next 5Y	-0.41%	ROE	-23.41%	52W High	42.27 -26.82%	Perf Year	71.17%
Cash/sh	10.77	P/FCF	-	EPS past 3/5Y	-171.13% -	ROIC	-18.75%	52W Low	6.43 381.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.16% 6.74%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-37.07%	Oper. Margin	-	ATR (14)	1.94	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	36.37	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.98	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	36.37	EPS Q/Q	-48.03%	SMA20	4.80%	Beta	1.66	Target Price	52.25
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	12.19%	Rel Volume	0.26	Prev Close	30.62
Employees	69	LT Debt/Eq	0.02	Earnings	Nov 06 BMO	SMA200	72.34%	Avg Volume	443.99K	Price	30.93
IPO	Jun 07, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.39% -	Trades		Volume	116,950	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-25	Initiated	BTIG Research	Buy	$47
Sep-16-25	Initiated	Truist	Buy	$44
Aug-06-25	Initiated	H.C. Wainwright	Buy	$31
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Dec-18-25 07:00AM	Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-25 12:00PM	Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know (Zacks)
Dec-05-25 09:00AM	Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures (GlobeNewswire)
Nov-28-25 09:55AM	Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? (Zacks)
Nov-25-25 07:00AM	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
09:55AM	Loading…
Nov-12-25 09:55AM	Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet (Zacks)
Nov-06-25 07:00AM	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Nov-05-25 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-30-25 11:49AM	JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success (Insider Monkey) +6.19%
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 04:05PM	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (GlobeNewswire)
Sep-09-25 09:17PM	Rapport Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.93% -20.09%
Sep-08-25 04:08PM	Rapport Stock Doubles After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily) +119.15%
04:05PM	Rapport Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:45AM	Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily)
09:28AM	Loading…
09:28AM	Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year (Benzinga)
06:00AM	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures (GlobeNewswire)
Sep-05-25 04:05PM	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 (GlobeNewswire) -6.45%
Aug-13-25 08:03AM	Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors (Business Wire)
Aug-07-25 07:00AM	Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update (GlobeNewswire) +5.48%
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat) -7.93%
Jun-02-25 02:45PM	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates (GlobeNewswire) +13.66%
May-27-25 07:00AM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) -7.21%
May-21-25 07:00AM	Rapport Therapeutics to Host 2025 Investor and Analyst Day (GlobeNewswire)
May-08-25 07:00AM	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Apr-22-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.27%
Mar-31-25 04:33AM	Rapport Therapeutics: Too Early To Be Interesting (Seeking Alpha)
Mar-21-25 07:00AM	Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-11-25 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +8.34%
Mar-03-25 07:00AM	Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development (GlobeNewswire) -28.71%
07:00AM	Loading…
Feb-24-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:20AM	Rapport Therapeutics announces new Phase 1 data for RAP-219 (TipRanks) -11.26%
Jan-09-25 09:12AM	CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
07:00AM	Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.64	5,833	172,877	567,913	Dec 18 04:11 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.63	5,083	150,632	30,895	Dec 18 04:11 PM
THE DOROTHY CEESAY IRREVOCABLE	Director	Dec 17 '25	Proposed Sale	30.76	15,249	469,059		Dec 17 04:28 PM
ABRAHAM CEESAY	Director	Dec 17 '25	Proposed Sale	30.76	17,499	538,269		Dec 17 04:25 PM
Bredt David	Chief Scientific Officer	Dec 15 '25	Sale	30.02	8,500	255,130	392,642	Dec 16 05:07 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Option Exercise	1.80	5,000	9,000	176,928	Dec 01 04:17 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Sale	30.10	5,000	150,486	171,928	Dec 01 04:17 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.19	5,833	146,931	573,746	Nov 18 04:27 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.20	5,083	128,116	35,978	Nov 18 04:27 PM
Bredt David	Chief Scientific Officer	Nov 17 '25	Sale	25.19	8,500	214,091	401,142	Nov 18 04:24 PM
Bredt David	Chief Scientific Officer	Oct 15 '25	Sale	25.79	8,500	219,196	409,642	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,833	150,541	579,579	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,083	131,189	41,061	Oct 16 04:30 PM
DAVID BREDT	Officer	Oct 15 '25	Proposed Sale	24.88	25,500	634,440		Oct 15 04:26 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	40,835	1,074,725	585,412	Sep 19 04:05 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	35,585	936,472	46,144	Sep 19 04:05 PM
ABRAHAM CEESAY	Director	Sep 17 '25	Proposed Sale	26.19	52,501	1,375,001		Sep 17 04:28 PM
THE DOROTHY CEESAY IRREV TRUST	Director	Sep 17 '25	Proposed Sale	26.19	45,751	1,198,219		Sep 17 04:26 PM
Bredt David	Chief Scientific Officer	Sep 15 '25	Sale	24.19	8,500	205,649	418,142	Sep 17 04:15 PM
Huber Reid M	Director	Sep 12 '25	Buy	24.48	20,400	499,374	20,400	Sep 15 04:05 PM
PAUL STEVEN M	Director	Sep 12 '25	Buy	24.65	41,666	1,027,111	41,666	Sep 15 04:05 PM
Young Wendy B.	Director	Sep 11 '25	Buy	22.60	3,500	79,100	9,500	Sep 11 06:13 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Option Exercise	1.80	5,000	9,000	176,928	Sep 10 04:15 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Sale	38.33	5,000	191,650	171,928	Sep 10 04:15 PM
CHERYL GAULT	Officer	Sep 08 '25	Proposed Sale	14.36	10,000	143,600		Sep 08 04:24 PM
Bredt David	Chief Scientific Officer	Aug 15 '25	Sale	15.00	8,500	127,466	426,642	Aug 18 05:14 PM
Bredt David	Chief Scientific Officer	Jul 15 '25	Sale	14.00	8,500	118,962	435,142	Jul 16 04:14 PM
Bredt David	Chief Scientific Officer	Jun 16 '25	Sale	11.00	8,500	93,522	443,642	Jun 18 04:15 PM
DAVID BREDT	Officer	Jun 16 '25	Proposed Sale	11.19	34,000	380,460		Jun 16 04:24 PM
Bredt David	Chief Scientific Officer	May 15 '25	Sale	9.56	8,500	81,262	452,142	May 19 04:30 PM
Bredt David	Chief Scientific Officer	Apr 15 '25	Sale	9.57	8,500	81,310	460,642	Apr 16 05:00 PM
Bredt David	Chief Scientific Officer	Mar 14 '25	Sale	10.85	8,500	92,205	469,142	Mar 17 05:00 PM
DAVID BREDT	Officer	Mar 14 '25	Proposed Sale	10.02	25,500	255,510		Mar 14 04:20 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 12 '25	Buy	10.10	9,900	99,990	9,900	Mar 13 05:13 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 13 '25	Buy	9.98	100	998	10,000	Mar 13 05:13 PM
Young Wendy B.	Director	Mar 12 '25	Buy	10.21	6,000	61,250	6,000	Mar 13 05:00 PM

Open in Screener

AVBP

ArriVent BioPharma Inc

Dec 24 • 02:25PM ET

22.29

-0.03 -0.13 %

Healthcare • Biotechnology • USA • NASD

AVBP ArriVent BioPharma Inc daily Stock Chart

Peers: AMGN SRPT VRTX REGN MRNA BIIB GILD IONS NBIX BLUE

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-4.24	Insider Own	36.30%	Shs Outstand	40.85M	Perf Week	0.22%
Market Cap	920.16M	Forward P/E	-	EPS next Y	-3.84	Insider Trans	0.00%	Shs Float	26.30M	Perf Month	3.63%
Enterprise Value	619.95M	PEG	-	EPS next Q	-0.87	Inst Own	70.51%	Short Float	25.66%	Perf Quarter	29.82%
Income	-151.40M	P/S	-	EPS this Y	-71.39%	Inst Trans	11.85%	Short Ratio	18.84	Perf Half Y	-2.28%
Sales	0.00M	P/B	2.99	EPS next Y	12.46%	ROA	-48.90%	Short Interest	6.75M	Perf YTD	-16.33%
Book/sh	7.47	P/C	3.06	EPS next 5Y	-3.47%	ROE	-51.98%	52W High	29.71 -24.97%	Perf Year	-14.56%
Cash/sh	7.27	P/FCF	-	EPS past 3/5Y	-15.72% -	ROIC	-49.64%	52W Low	15.47 44.09%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.33% 6.53%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-75.31%	Oper. Margin	-	ATR (14)	1.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.90	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.02	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.90	EPS Q/Q	-36.74%	SMA20	-3.79%	Beta	0.97	Target Price	40.75
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	6.34%	Rel Volume	0.22	Prev Close	22.32
Employees	52	LT Debt/Eq	0.00	Earnings	Nov 10 BMO	SMA200	9.52%	Avg Volume	358.09K	Price	22.29
IPO	Jan 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.16% -	Trades		Volume	77,002	Change	-0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Initiated	BTIG Research	Buy	$45
Nov-25-25	Initiated	Truist	Buy	$43
Jul-10-25	Resumed	Goldman	Buy	$33
Mar-20-25	Initiated	B. Riley Securities	Buy	$37
Mar-10-25	Initiated	Guggenheim	Buy	$45
Jul-22-24	Initiated	Oppenheimer	Outperform	$35
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

Dec-23-25 08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-22-25 08:00AM	ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Nov-10-25 08:00AM	ArriVent BioPharma Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Sep-22-25 04:05PM	ArriVent Appoints Brent S. Rice as Chief Commercial Officer (GlobeNewswire) +5.50%
08:00AM	Loading…
Sep-09-25 08:00AM	Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer (GlobeNewswire)
Aug-11-25 08:00AM	ArriVent BioPharma Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-21-25 08:00AM	ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 (GlobeNewswire)
06:08AM	New Strong Sell Stocks for July 21st (Zacks)
Jul-01-25 11:15PM	ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:05PM	ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-23-25 07:00AM	ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study (GlobeNewswire) -9.60%
Jun-20-25 04:05PM	ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC (GlobeNewswire)
May-12-25 08:00AM	ArriVent BioPharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 08:00AM	ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
04:23PM	Loading…
Mar-19-25 04:23PM	ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts (Insider Monkey)
Mar-03-25 07:00AM	ArriVent BioPharma Reports Full Year 2024 Financial Results (GlobeNewswire) -6.69%
Jan-23-25 07:05AM	ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright (TipRanks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +5.22%
Jan-21-25 07:00PM	ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers (GlobeNewswire)
Nov-14-24 08:00AM	ArriVent BioPharma Reports Third Quarter 2024 Financial Results (GlobeNewswire) -11.86%
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc (GuruFocus.com)
Sep-09-24 12:05PM	ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer (GlobeNewswire)
Aug-19-24 09:55AM	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
Aug-14-24 09:54PM	AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	ArriVent BioPharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer (GlobeNewswire)
Jun-05-24 07:00AM	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab (GlobeNewswire)
May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Loading…
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaChapelle Robin	Chief Operating Officer	Jul 11 '25	Option Exercise	2.28	11,153	25,429	135,736	Jul 15 07:00 AM

BIOA

BioAge Labs Inc

RAPP

Rapport Therapeutics Inc

AVBP

ArriVent BioPharma Inc

Upgrade your FINVIZ experience